Release Date: 21/01/16 08:35 Summary: BRS Directors recommend shareholders reject Ferrovial Offer Price Sensitive: Yes Download Document 156.52KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%